Sort   by:  
 Page size 
UnknownHigh levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
Not available
S-EPMC10725394 | biostudies-literature
GenomicsThe IMiDs, through loss of Ikaros and Aiolos, primes myeloma cells for daratumumab mediated killing by upregulation of CD38
The IMiDs, through loss of Ikaros and Aiolos, primes myeloma cells for daratumumab mediated killing by upregulation of CD38
PRJNA449831 | ENA
UnknownIMiDs induce FAM83F degradation via an interaction with CK1α to attenuate Wnt signalling.
Not available
S-EPMC7768194 | biostudies-literature
UnknownIMiDs Augment CD3-Bispecific Antibody-Induced CD8+ T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production.
Not available
S-EPMC10157361 | biostudies-literature
TranscriptomicsThe IMiDs, through loss of Ikaros and Aiolos, primes myeloma cells for daratumumab mediated killing by upregulation of CD38
Recent studies have demonstrated that the immunomodulatory drugs (IMiDs) lead to the degradation of the transcription factors Ikaros and Aiolos. However, why their loss subsequently leads to multiple myeloma (MM) cell death remains unclear. Using CRISPR-Cas9 genome editing, we have deleted IKZF1 and...
ORGANISM(S): Homo sapiens 
2018-09-12 | GSE113031 | GEO
ProteomicsTargeted MS assay to evaluate Cereblon neosubstrate changes in rabbit embryos following maternal administration of IMiDs
Targeted protein degradation is the selective removal of a protein of interest through hijacking intracellular protein cleanup machinery. This rapidly growing field currently relies heavily on the use of the E3 ligase Cereblon (CRBN) to target proteins for degradation, including the immunomodulatory...
ORGANISM(S): Oryctolagus Cuniculus 
PXD050568 | panorama
UnknownIntegration of Immunome With Disease-Gene Network Reveals Common Cellular Mechanisms Between IMIDs and Drug Repurposing Strategies.
Not available
S-EPMC8181425 | biostudies-literature
ProteomicsNovel molecular glue degraders against broad range of myeloma and lymphoma cancer cell lines
Targeted protein degradation of neosubstrates plays a crucial role in treating hematological cancers with IMiDs therapy. However, the inevitable drug resistance and hematological toxicities remain persistent challenges, limiting their clinical efficacy. Herein, we present the discovery of a lead deg...
ORGANISM(S): Homo Sapiens 
PXD053334 |
UnknownInternal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma.
Not available
S-EPMC4091528 | biostudies-literature
TranscriptomicsTreatment of MM cells with IMiDs or reducing the expression of EIF2C2 significantly affects steady-state levels of miRNAs
Lenalidomide is a therapeutically active compound that binds to E3 ubiquitin ligase recruiter cereblon (CRBN) and induces cytotoxicity. We have identified eukaryotic translation initiation factor 2 subunit C2 (EIF2C2) as a new member of CRBN-downstream binding protein that plays an important role in...
ORGANISM(S): Homo sapiens 
2016-03-09 | GSE61693 | GEO
Sort   by:  
 Page size